Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, KO | - |
dc.contributor.author | Lee, T | - |
dc.contributor.author | Lee, N | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Yang, EG | - |
dc.contributor.author | Yoon, JM | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Lee, TG | - |
dc.contributor.author | Park, H | - |
dc.date.accessioned | 2024-01-21T04:05:42Z | - |
dc.date.available | 2024-01-21T04:05:42Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2005-12 | - |
dc.identifier.issn | 0026-895X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/135971 | - |
dc.description.abstract | Hypoxia-induced gene expression is initiated when the hypoxiainducible factor-1 (HIF-1) alpha subunit is stabilized in response to a lack of oxygen. An HIF-1 alpha-specific prolyl-hydroxylase (PHD) catalyzes hydroxylation of the proline-564 and/or -402 residues of HIF-1 alpha by an oxygen molecule. The hydroxyproline then interacts with the ubiquitin E3 ligase von Hippel Lindau protein and is degraded by an ubiquitin-dependent proteasome. PHD2 is the most active of three PHD isoforms in hydroxylating HIF-1 alpha. Structural analysis showed that the N-terminal region of PHD2 contains a Myeloid translocation protein 8, Nervy, and DEAF1 (MYND)-type zinc finger domain, whereas the catalytic domain is located in its C-terminal region. We found that deletion of the MYND domain increased the activity of both recombinant PHD2 protein and in vitro-translated PHD2. The zinc chelator N, N, N', N'-tetrakis(2-pyridylmethyl) ethylenediamine augmented the activity of wild-type PHD2-F but not that of PHD2 lacking the MYND domain, confirming that the zinc finger domain is inhibitory. Overexpression of PHD2 lacking the MYND domain caused a greater reduction in the stability and function of HIF-1 alpha than did overexpression of wild-type PHD2, indicating that the MYND domain also inhibits the catalytic activity of PHD2 in vivo. | - |
dc.language | English | - |
dc.publisher | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | - |
dc.subject | UBIQUITIN-PROTEASOME PATHWAY | - |
dc.subject | PROLYL HYDROXYLATION | - |
dc.subject | FACTOR 1-ALPHA | - |
dc.subject | HIF PROLYL | - |
dc.subject | PROTEIN | - |
dc.subject | TRANSCRIPTION | - |
dc.subject | FAMILY | - |
dc.subject | DOMAIN | - |
dc.subject | ALPHA | - |
dc.subject | GENE | - |
dc.title | Inhibition of the catalytic activity of hypoxia-inducible factor-1 alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger | - |
dc.type | Article | - |
dc.identifier.doi | 10.1124/mol.105.015271 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | MOLECULAR PHARMACOLOGY, v.68, no.6, pp.1803 - 1809 | - |
dc.citation.title | MOLECULAR PHARMACOLOGY | - |
dc.citation.volume | 68 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1803 | - |
dc.citation.endPage | 1809 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000233340200031 | - |
dc.identifier.scopusid | 2-s2.0-27844605466 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | UBIQUITIN-PROTEASOME PATHWAY | - |
dc.subject.keywordPlus | PROLYL HYDROXYLATION | - |
dc.subject.keywordPlus | FACTOR 1-ALPHA | - |
dc.subject.keywordPlus | HIF PROLYL | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | FAMILY | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordPlus | ALPHA | - |
dc.subject.keywordPlus | GENE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.